Protein kinase D2 (PKD2) is a member of the PKD family of serine/threonine kinases, a subfamily of the CAMK super-family. PKDs have a critical role in cell motility, migration and invasion of cancer cells. Expression of PKD isoforms is deregulated in various tumours and PKDs, in particular PKD2, have been implicated in the regulation of tumour angiogenesis. In order to further elucidate the role of PKD2 in tumours, we investigated the signalling context of this kinase by performing an extensive substrate screen by in vitro expression cloning (IVEC). We identified a novel splice variant of calcium and integrin-binding protein 1, termed CIB1a, as a potential substrate of PKD2. CIB1 is a widely expressed protein that has been implicated in angiogenesis, cell migration and proliferation, all important hallmarks of cancer, and CIB1a was found to be highly expressed in various cancer cell lines. We identify Ser 118 as the major PKD2 phosphorylation site in CIB1a and show that PKD2 interacts with CIB1a via its alanine and proline-rich domain. Furthermore, we confirm that CIB1a is indeed a substrate of PKD2 also in intact cells using a phosphorylation-specific antibody against CIB1a-Ser 118 . Functional analysis of PKD2-mediated CIB1a phosphorylation revealed that on phosphorylation, CIB1a mediates tumour cell invasion, tumour growth and angiogenesis by mediating PKD-induced vascular endothelial growth factor secretion by the tumour cells. Thus, CIB1a is a novel mediator of PKD2-driven carcinogenesis and a potentially interesting therapeutic target.
INTRODUCTION
The protein kinase D (PKD) family belongs to the calcium/ calmodulin-dependent protein kinase super-family and comprises PKD1, PKD2 and PKD3. 1 PKDs are activated either directly via phorbol esters or indirectly by various mechanisms including G protein-coupled receptors. 2 These kinases participate in many key signalling pathways in a diverse range of cells and are involved in fundamental biological processes: PKDs have a critical role in motility, migration and invasion of cancer cells. [3] [4] [5] [6] PKD isoforms, in particular PKD2, are highly expressed in certain tumours 7, 8 and have been implicated in the regulation of tumour cell proliferation and apoptosis. 9, 10 Recently, we and other laboratories have demonstrated that PKD1 and PKD2 have critical roles in vascular biology and angiogenesis. 7, [11] [12] [13] [14] [15] PKD2 is a pivotal mediator of vascular endothelial growth factor (VEGF)-induced endothelial cell (EC) proliferation and migration and regulates the expression of VEGF receptor-2 and the production of cytokines in ECs. 13 Furthermore, PKD2 has a major role in tumour angiogenesis by mediating hypoxia-induced VEGF production and secretion in tumour cells, as well as VEGFinduced signalling in the tumour-associated ECs.
7 PKD2 downstream targets responsible for its effect on angiogenesis are as yet incompletely understood.
For a better understanding of the precise signalling context of PKD2, in particular with respect to angiogenesis, we used in vitro expression cloning (IVEC) to identify potential novel PKD substrates that could have an impact on angiogenesis. One potentially novel substrate identified in the screen was a splice variant of human calcium and integrin-binding protein 1 (CIB1) that we termed CIB1a (GenBank accession number: BankIt1498958 Seq1 JQ246073).
CIB1 is a 22-kDa EF-hand-containing protein identified originally as a binding partner of the platelet integrin aIIb, and later found to inhibit aIIbb3 activation in megakaryocytes. 16, 17 CIB1 is widely expressed 18, 19 and has a role in angiogenesis. Apparently, it is not required for developmental angiogenesis, as CIB1-KO mice are viable and female mice are fertile, but is essential for proper EC signalling and functions such as migration, proliferation and nascent tubule formation. 20, 21 Loss of CIB1 in ECs results in attenuated responses to angiogenic growth factors such as VEGF and fibroblast growth factor 2 (FGF2), and consequently decreased expression of the matrix-degrading proteinase matrix metalloproteinase 2. CIB1 expression in the host also promotes tumour growth and tumour-induced angiogenesis by an as yet unknown mechanism.
22 CIB1 physically associates with proteins such as the transcription factor PAX3, 23 the inositol 1, 4, 5-trisphosphate receptor, 24 polo-like kinases, 18, 25 Rac 3, 26 focal adhesion kinase (FAK) 27 and p21-activated kinase (PAK1). 28 Among these binding partners, PAK1 and FAK regulate EC function and angiogenesis in vitro or in vivo.
Here we identify a novel splice variant of CIB1, termed CIB1a, as a substrate of PKD2 both in vitro and in intact cells, and found Ser 118 as the major PKD2 phosphorylation site in CIB1a. Our data also show that CIB1a specifically interacts with the N-terminal alanine and proline (AP)-rich domain of PKD2. CIB1a phosphorylation by PKD2 results in increased VEGF-A secretion by the tumour cells in vitro and stimulates tumour growth and tumour angiogenesis on the chicken chorioallantois and enhances tumour cell invasion, making CIB1a a novel downstream mediator of the pro-angiogenic properties of PKD2 in cancer.
RESULTS

Identification of potential PKD2 substrates involved in angiogenesis
To identify potential novel PKD2 substrates that could mediate the effect of PKD2 in tumour angiogenesis, we performed IVEC. 32 Pools of approximately 100 clones from a complementary DNA (cDNA) library were transcribed and translated in vitro, and the resulting S 35 -labelled protein pools were incubated with or without catalytically active PKD2 (PKD2-2SE) and subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Phosphorylation of potential substrates was assessed by the kinase-dependent alteration in electrophoretic mobility ( Figure 1a , upper panel). Positive cDNA pools were progressively subdivided and single cDNA sub-pools were re-assayed for the presence of a kinase-induced mobility shift ( Figure 1a , lower panel). This procedure yielded specific cDNAs encoding putative PKD2 substrates. One positive clone with an open reading frame of 697 bp encoding a polypeptide with a predicted mass of 26 kDa corresponded to a splice variant of the human CIB1. As CIB1 has been implicated in angiogenesis, we decided to further examine this clone, which we termed CIB1a. CIB1a is generated by an intron retaining mode of splicing and has an additional 120 bp located in the coding region of N-terminal part of cDNA. The retained part of the intron encodes amino acids properly, containing no stop codon and causing no shift in the reading frame (Supplementary Figure S1) .
To confirm that CIB1a is a direct substrate of PKD2, we generated recombinant CIB1a protein from bacteria. Phosphorylation of CIB1a by PKD2 was analysed by in vitro kinase (IVK) assays. Wild-type PKD2 (PKD2-WT) phosphorylated CIB1a in vitro. CIB1a phosphorylation was substantially enhanced when PKD2 was activated by phorbol 12-myristate 13-acetate (PMA) or on incubation with constitutively active PKD2 (PKD2-2SE). In contrast, CIB1a phosphorylation was virtually undetectable in the presence of catalytically inactive PKD2 (PKD2-DA; Figure 1b) . Thus, PKD2 phosphorylates CIB1a in vitro.
CIB1 is widely expressed in normal human tissues. 19 Interestingly, high levels of CIB1 expression were observed in breast cancer cell lines and tissues 18 as well as in bladder, cervix and colorectal cancer using microarrays and serial analysis of gene expression (SAGE) (GeneNote, http://bioinfo2.weizmann.ac.il; GeneCards; http://www.genecards.org). To determine the expression of CIB1 and CIB1a in various human cancer cell lines, we analysed their expression by reverse transcriptase-PCR using primers designed to amplify both a 0.4-kb fragment of CIB1 and a 0.5-kb fragment of CIB1a (Figure 1c ). We detected a single 0.4-kb band in all cell lines examined ( Figure 1c , upper panel), indicating the presence of CIB1-specific mRNA. We speculated that the CIB1a isoform might have also been amplified, but this could not be demonstrated in the same PCR reaction. Therefore, CIB1a was re- 35 S-labelled protein pools were generated by in vitro transcription and translation of a plasmid based, human adult brain cDNA library, using Promega's Gold TnT SP6 Express 96 coupled Transcription and Translation System and incubated with ( þ ) or without ( À ) catalytically active PKD2 (PKD2-2SE (S 706/710 E)). Potential substrates exhibit a slower relative mobility because of phosphorylation by PKD2-2SE. Alteration in the electrophoretic mobility is indicated with arrows (a, lower panel). amplified from the same reaction using CIB1a-specific primers ( Figure 1c , lower panel) and could then be detected in all cell lines examined. To determine the expression of CIB1a in the respective cell lines at the protein level, we performed western blot analysis using an antibody directed against the C-terminus of CIB1. The antibody detected both overexpressed CIB1 and CIB1a (Figure 1d , upper panel). CIB1a could be differentiated from CIB1 because of its slower mobility in SDS-PAGE. Interestingly, the predominant endogenous isoform expressed in the tumour cells was CIB1a (Figure 1d, lower panel) . Taken together, these results show that the splice variant of CIB1, CIB1a, is novel PKD2 substrate and is highly expressed in cancer cells.
Identification of the PKD2 phosphorylation site/s in CIB1a To determine the site in CIB1a that is phosphorylated by PKD2, we performed an in silico analysis using the Scansite algorithm. 33 This search revealed two sequences, ERICRVFSTSPAKDS and SDIDRDGTINLFEFQ that resemble PKD substrate phosphorylation motifs (LXRXX (T*/S*). 34 Both sequences have a basic residue at position À 3 (arginine (R)) and an aliphatic residue at position À 5 (isoleucine (I)) with respect to the phosphorylatable serine (S)/ threonine (T), as indicated by bold alphabets. In addition, we examined whether the respective serine and threonine residues were positioned at the surface of the protein of interest. To this end, a three-dimensional computer model of the CIB1a protein structure was generated using the DeepView/Swiss-PdbViewer based on the known crystal structure of CIB1 35 ( Figure 2a ). This model revealed that both potential phosphorylation sites, Ser 118 and Thr 207 , were surface accessible. Next, we generated fusion proteins of CIB1a in which Ser 118 or Thr 207 were substituted with alanine. These proteins were subjected to IVK assays with PKD2. Exchanging Ser 118 to Ala abrogated phosphorylation of CIB1a by PKD2. In contrast, the CIB1a-Thr 207 Ala mutant showed a similar level of phosphorylation by PKD2 compared with the wild-type protein (Figure 2b) . Thus, Ser 118 , but not Thr 207 , is the major PKD2 phosphorylation site in CIB1a.
To determine whether Ser 118 is also a major CIB1a phosphorylation site in vivo, we generated a phospho-specific antibody directed against the CIB1a-derived peptide CRVFpSTSPAKDS (pS Figure  S2A) . Furthermore, PMA-induced phosphorylation of endogenous CIB1a that was abolished by PKD2 knockdown (Supplementary Figure S2B) .
Next, cells were transfected with Myc-tagged CIB1a expression plasmids (wild type, CIB1a-S 118 A or CIB1a-S 118 E) together with various PKD2 constructs, as indicated ( Figure 2d Figure 2d ).
Thus, CIB1a is a physiological substrate of PKD2 and Ser 118 is the relevant PKD2 phosphorylation site.
CIB1a interacts with PKD2
Having established that CIB1a is a novel PKD2 substrate, we next examined whether CIB1a and PKD2 would physically interact. Endogenous PKD2 was immunoprecipitated, and the immunoprecipitate was probed for the presence of endogenous CIB1a and vice versa. As shown in Figure 3b , both proteins interacted, regardless of the order of immunoprecipitation. This interaction was confirmed by co-immunoprecipitation assays using ectopically expressed enhanced green fluorescent protein (EGFP)-PKD2 and Myc-CIB1a in HEK293-T cells: EGFP-PKD2 was detectable in Myc-CIB1a immunoprecipitates, and Myc-CIB1a was found in EGFP-PKD2 immunoprecipitates ( Figure 3d ). The data shown in Figure 3b suggested that there might be a slight decrease in the interaction between PKD2 and CIB1a on activation of the kinase/ phosphorylation of the substrate. To further investigate whether this interaction was indeed dependent on the catalytic activity of PKD2, we performed pull-down assays using exogenously expressed, GFP-tagged wild type, catalytically active or inactive PKD2 mutants. As shown in Figure 3c , CIB1a interacted with both, constitutively active PKD2-SE and kinase-dead PKD2-DA suggesting that the interaction between both proteins is constitutive. However, a quantitative analysis of the interaction between phosphomimetic CIB1a-S 118 E or non-phosphorylatable CIB1a-S 118 A and PKD2 revealed that phosphorylated CIB1a interacts less with PKD2. This suggests that phosphorylation of CIB1a releases at least to some degree the protein from its interaction with PKD2 (Supplementary Figure 3A) .
Next, we were interested which domains in PKD2 would mediate the interaction with CIB1a. The three members of the PKD family (PKD1, PKD2 and PKD3) share a unique modular structure consisting of two N-terminal cysteine-rich Zn-fingers, a central pleckstrin homology (PH) domain and a C-terminal Ser/Thr protein kinase domain. 1 The N-terminus of PKD1 and PKD2 starts with a hydrophobic region rich in AP residues. This region is missing in PKD3. To identify the site where PKD2 interacts with CIB1a, we incubated various mutants of PKD2 as indicated in Figure 3a together with recombinant glutathione S-transferase (GST)-tagged CIB1a. Interestingly, GST-CIB1a interacted with PKD2 lacking its cysteine-rich domain, the PH domain and even the catalytic domain.
However, interaction of PKD2 and CIB1a was lost when the N-terminal AP-rich region of PKD2 was missing (Figure 3c ). Thus, CIB1a is likely to interact with this N-terminal region of PKD2. Consequently, CIB1a also interacted with PKD1, but failed to interact with PKD3 that lacks the N-terminal polar domain (Figure 3d ).
To further examine whether the interaction between PKD2 and CIB1a could be biologically meaningful, we examined the subcellular localization of CIB1a using GFP-tagged CIB1a expression plasmids. CIB1a was detectable ubiquitously in the cytoplasm and the nucleus of HeLa cells independently of its phosphorylation status at Ser
118
. A more localized CIB1a immunofluorescence was detectable in the perinuclear compartment where it colocalized with Golgin 97, a Trans-Golgi resident protein ( Figure 3e ). As we have shown previously that PKD2 localizes to the nucleus, the cytoplasm and in particular to the trans-Golgi network (TGN) in HeLa cells where it colocalizes with Golgin 97, [36] [37] [38] we conclude that CIB1a and PKD2 occur at similar subcellular localizations in tumour cells. Taken together, CIB1a and PKD2 are localized at the same subcellular compartments and physically interact with each other. PKD2 interacts within its N-terminal AP-rich region with CIB1a, and regulates the interaction via its catalytic activity.
Expression of phosphomimetic CIB1a-S 118 E in tumour cells results in increased tumour growth and angiogenesis in the chorioallantois membrane (CAM) model Both PKD2 and CIB1 have been shown to have a role in tumour growth and angiogenesis. 7, 22, 39, 40 Our data show that PKD2 phosphorylates CIB1a at Ser 118 . To determine whether phosphorylation of CIB1a at this site affects tumour formation and angiogenesis in an in vivo setting, we examined the growth of HeLa cells expressing CIB1a-WT, non-phosphorylatable CIB1a (CIB1a-S 118 A) or a phosphomimetic CIB1a mutant (CIB1a-S 118 E) on the chicken CAM, a widely used model to study in vivo tumour formation and angiogenesis. 41, 42 Tumour formation was assessed after 4 days of incubation. Tumours derived from cancer cells overexpressing the phosphomimetic CIB1a-S 118 E mutant were significantly larger, compared with tumour cells expressing CIB1a-WT or CIB1a-S 118 A as assessed by measuring the tumour area within the silicon ring and by histological analysis, (Figures 4a and  b) . Vice versa, tumours derived from cells expressing the nonphosphorylatable CIB1a-S 118 A mutant were significantly smaller than those expressing CIB1a-WT. Consequently, compared with CIB1a-WT or CIB1a-S 118 A-expressing tumours, tumours derived from cancer cells expressing CIB1a-S 118 E exhibited a significantly increased proliferation index, as evidenced by the number of Ki-67-positive tumour cells (Figures 4d and e) .
To confirm that CIB1a is a mediator of PKD2-induced tumour growth in this assay, we performed rescue experiments with CIB1a expression plasmids in Hela cells where PKD2 had been depleted by short hairpin RNA (shRNA). Selective PKD2 knockdown significantly reduced tumour growth on the CAM (Supplementary Figures S4B-D) . However, tumour growth was partially restored in tumours developing from cells expressing CIB1a-S 118 E. These tumours were significantly larger than tumours developing from PKD2-depleted HeLa cells expressing CIB1a-WT or CIB1a-S 118 A, respectively (Supplementary Figures S4B-D) . The effect of CIB1a-S 118 E on tumour growth could be the result of a direct stimulation of tumour cell proliferation or could be mediated indirectly. To examine whether CIB1a-S 118 E directly affects tumour cells proliferation, we performed cell cycle analyses in HeLa cells expressing CIB1a-WT, CIB1a-S 118 A or CIB1a-S 118 E, respectively. As shown in Supplementary Figure S4E , there was no increase in the percentage of cells in S phase expressing the CIB1a-S 118 E mutant. These data suggest that CIB1a-S 118 E promotes tumour growth on the CAM by an indirect mechanism.
Both, PKD2 and CIB1a have been implicated in angiogenesis and the CAM assay is an excellent assay to study tumour CIB1a mediates PKD2-induced tumour growth and angiogenesis M Armacki et al angiogenesis in vivo. Thus, we examined whether CIB1a-S 118 E may exert its tumour-promoting effect indirectly by modulating tumour angiogenesis. To evaluate the effect of PKD2-induced CIB1a phosphorylation on tumour angiogenesis, at first we performed immunohistochemistry using antibodies directed against von Willebrand factor and desmin to identify neoplastic vessels. 7 As shown in Figure 5a , there was a significant increase in von Willebrand factor and desmin immunoreactivity surrounding tumour cells in the CAM when the cells expressed CIB1a-S 118 E compared with CIB1a wild-type or non-phosphorylatable CIB1a-S 118 A. Figures 5b and c represent the quantification of the immunohistochemistry shown in Figure 5a . Thus, CIB1a phosphorylated by PKD2 markedly stimulates tumour angiogenesis, whereas CIB1a-WT and CIB1a-S 118 A have no effect on tumour angiogenesis and angiogenesis could be a potential mechanism explaining the growth-promoting effect of CIB1a-S 118 E. It has been reported previously that CIB1 protein binds to and regulates the activity of PAK1 28 and FAK, 27 both kinases that are known contribute to angiogenesis. 30, 31, 43 Also CIB1a interacted with both FAK and PAK1, however, the interaction was independent of its phosphorylation at Ser118 (Supplementary Figures S5A and S6A, Figure S5B) . However, both CIB1a-S 118 A and -S 118 E had no additional effect on FAK tyrosine phosphorylation compared with CIB1a-WT. The catalytic activity of PAK1 was not affected on overexpression of CIB1a-WT, CIB1a-S 118 E or CIB1a-S 118 A, respectively, as determined by IVK assays (Supplementary Figure S6B) . Thus, we can exclude FAK and PAK1 as potential mediators of the proangiogenic effect of CIB1a-S 118 E. Along with others, we have previously shown that HDAC5, via the nuclear orphan receptor Nur77, mediates PKD2-induced tumour angiogenesis. 12 Thus, we examined whether CIB1a has an effect on HDAC5 regulated genes such as Nur77. 12, 44 As shown in Supplementary Figure 7A , CIB1a moderately induced Nur77 transcription, but there was no further change in Nur77 transcription in the presence of either CIB1a mutant. Thus, CIB1a can regulate Nur77 transcriptional activity, but this effect does not contribute to its proangiogenic effect on phosphorylation by PKD2.
As FAK, PAK and HDAC5 signalling pathways were not affected by PKD2-phosphorylated CIB1a, we examined whether CIB1a was involved in the secretion of pro-angiogenic cytokines that are also enhanced by active PKD2. 
CIB1a-S 118 E stimulates VEGF-A secretion by the tumour cells
We have previously shown that PKD2 mediates hypoxia-induced VEGF-A expression in and VEGF-A secretion by epithelial tumour cells. 7 As PKD2-induced phosphorylation of CIB1a stimulates angiogenesis, we reasoned that CIB1a, as a substrate of PKD2, could be an important downstream mediator of VEGF-A expression under hypoxic conditions. At first, we examined whether hypoxia would stimulate phosphorylation of CIB1a at Ser 118 . As shown in Figure 7a (top panel), hypoxia as indicated by increased expression of the hypoxia-inducible factor prolyl-4-hydroxylase, PHD2, increased phosphorylation of endogenous CIB1a. Thus, hypoxia that activates PKD2 also induces phosphorylation of its substrate CIB1a at Ser 118 . Next, we analysed VEGF-A expression in tumour tissues and the peritumoural area by immunohistochemistry in tumours expressing CIB1a-WT, CIB1a-S 118 E or CIB1a-S 118 A, respectively. CIB1a-S 118 E-expressing tumours exhibited significantly increased VEGF-A immunoreactivity in the tumour cells, the ECs and in particular in the extracellular matrix (ECM) surrounding the tumour cells compared with CIB1a or CIB1a-S 118 A-expressing tumours ( Figure 6 ). Indeed, VEGF-A immunoreactivity was barely detectable in the stroma of tumours expressing CIB1a-S 118 A (Figures 6a and c) . The high VEGF-A immunoreactivity in the stroma of CIB1a-S 118 E tumours suggests that CIB1a phosphorylation might regulate VEGF production and/ or secretion in the tumour cells.
Therefore, we next examined whether CIB1a would have an effect of VEGF-A expression in Hela cells. HeLa cells were transfected with scrambled or CIB1a-specific small interfering RNA (siRNA) oligonucleotides and subsequently with a VEGF-A-luc CIB1a mediates PKD2-induced tumour growth and angiogenesis M Armacki et al promoter plasmid and then exposed to a normoxic or hypoxic atmosphere, respectively. Depletion of CIB1a in the tumour cells decreased the VEGF-A promoter activity by 40% under hypoxic conditions (Figure 7a ). Hypoxia induced a 70% increase in VEGF-A promoter activity in cells expressing CIB1a-WT. VEGF promoter activity was not significantly further enhanced when cells expressed the phosphomimetic CIB1a-S 118 E mutant (Supplementary Figure S7B) . These data confirm previous data showing that CIB1 can regulate VEGF-A promoter activity, but also indicate that PKD2-induced CIB1a phosphorylation does not affect this process.
To examine a potential effect of PKD2-mediated CIB1a phosphorylation on VEGF secretion, we determined the amount of VEGF-A protein in the supernatant of HeLa cells expressing CIB1a-WT, CIB1a-S 118 A or CIB1a-S 118 E, and in the supernatant of cells transfected with scrambled siRNA or siRNA oligonucleotides that specifically target PKD2 either under normoxic or hypoxic conditions. The hypoxic environment was verified by upregulation of HIF1alpha as detected by western blotting (Figure 7b ). Hypoxiainduced VEGF-A secretion by cells expressing the phosphomimetic CIB1a-S 118 E mutant was significantly increased compared with VEGF-A secretion by cells expressing wild-type or nonphosphorylatable CIB1a-S 118 A (Figure 7b ). Depletion of PKD2 led to a decrease in hypoxia-induced VEGF-A secretion, in accordance with our previous data. 7 These data indicate that the PKD2-induced CIB1a phosphorylation is not required for hypoxia-induced VEGF-A expression, but it regulates VEGF-A secretion by the tumour cells downstream of PKD2.
PKD2 regulates vesicular transport from the TGN to plasma membrane. Therefore, we tested whether CIB1a as PKD2 downstream target had an effect on vesicular transport 37 using secretory form of the peroxidase (ssHRP) as a marker. 45, 46 In cells expressing CIB1a-WT, peroxidase (ssHRP) was efficiently secreted into the supernatant (Figure 7c ). The amount of secreted peroxidase (ssHRP) was significantly increased in cells expressing the phosphomimetic CIB1a-S 118 E mutant compared with CIB1a-WT and CIB1a-S 118 A (Figure 7c ). Thus, CIB1a contributes to the transport of cargo from the TGN to the plasma membrane downstream of PKD2. These data are in accordance with our finding that CIB1a is localized at the TGN in HeLa cells (Figure 3e) . Furthermore, colocalization studies using the pSer 118 -CIB1a antibody revealed that CIB1a phosphorylated at Ser 118 almost exclusively localizes to the TGN further supporting a role of phosphorylated CIB1a at the TGN (Figure 7d ). The effect of CIB1a on protein transport was specific. CIB1a did not affect secretion of another proangiogenic cytokine, FGF2, which has been shown to be secreted by an ER-Golgi-independent mechanism, 47-49 under both normoxic hypoxic condition (Supplementary Figure S7C) . Phosphorylated CIB1a stimulates tumour cell invasion Tumour invasion is dependent on angiogenesis and both, PKDs and VEGF-A can promote tumour cell invasion. [50] [51] [52] Therefore, we examined whether tumours expressing CIB1a-S118E would also 118 . HeLa cells cultured under normoxic (N) or hypoxic (H) conditions for 24 h were lysed and endogenous CIB1a was immunoprecipitated using the Catch and Release Kit (500 mg of cell lysate). Phosphorylation of CIB1a in response to hypoxia was detected using the anti-phospho CIB1aSer 118 antibody. Hypoxic conditions were verified by examining PHD2 expression. (a, middle) CIB1a mediates hypoxia-induced VEGF-A promoter activation in epithelial tumour cells. HeLa cells transfected with CIB1a-specific (siCIB) or scrambled (siCon) siRNA oligonucleotides were subsequently transfected with pGL2-VEGF-A-Luc and pTK-Renilla for 8 h. Cells were subsequently incubated for 24 h under normoxic or hypoxic conditions and the cell lysates were subjected to luciferase assay. (a, bottom) CIB1a knockdown, hypoxia and equal loading of proteins were verified by western blotting using CIB1a, HIF1a and actin antibodies, respectively. (b) Phosphorylation of CIB1a enhances hypoxia-induced VEGF-A secretion by epithelial tumour cells. HeLa cells were transfected with wild type, non-phosphorylatable CIB1a-S 118 A, or phosphomimetic CIB1a-S 118 E mutants, or PKD2-specific (siPKD2) or scrambled siRNA oligonucleotides, respectively. Cells were subsequently incubated under normoxic or hypoxic conditions for 12 h. VEGF-A was determined in supernatant of the tumour cells using a specific ELISA. Hypoxic conditions were verified by western blotting against HIF1a. (c) The PKD2 substrate CIB1a mediates protein transport. ss-HRP and CIB1a-WT, or CIB1a-S 118 A or CIB1a-S 118 E were co-transfected in HeLa cells. 24 h after transfection, growth medium was replaced and HRP activity secreted in the medium was measured after 0 h and 2 h by chemiluminescence. Bars represent the means ± s.e.m. of three independent experiments of HRP activity in the medium normalized to intracellular ss-HRP expression levels. Protein expression was verified in WCL by immunoblotting with anti-CIB (for CIB1a). Bars are the means ± s.e.m. of the three independent experiments (T-test: *Po0.05; **Po0.001). (d) CIB1a phosphorylated at serine 118 is detectable predominantly in the perinuclear compartment. HeLa cells co-expressing a wild-type EGFP-CIB1a and pcDNA3-PKD2-DA or pcDNA-PKD2-SE were fixed followed by anti-Golgin97/Alexa568 and anti-phospho-Ser 118 /Alexa647 immunostaining. Arrows indicate localization of GFP-CIB1a and phospho-Ser118-CIB1a. Inlet displays localization of phospho-Ser 118 -CIB1a at TGN. NS, not significant.
CIB1a mediates PKD2-induced tumour growth and angiogenesis M Armacki et al exhibit distinct invasive properties. Indeed, tumours expressing CIB1a-S 118 E were highly invasive on the CAM as judged by the number of invading cytokeratin-positive tumour cells (Figures 4d  and 8a) . Invasion of the CIB1a-S 118 E-expressing tumours was far more pronounced than that of tumours expressing CIB1a wild type and was barely detectable in tumours expressing CIB1a-S 118 A (Figure 8a) .
The migratory properties of tumours cells expressing the various CIB1a mutants were assessed in vitro using a transwell matrigel assay. [53] [54] [55] [56] Thus, these data establish CIB1a also as a downstream mediator of PKD2-induced tumour cell invasion.
DISCUSSION
PKDs are emerging as potentially important mediators of tumour growth, invasion and tumour angiogenesis, which results in a growing interest in the development of strategies to target these kinases. 39, 40, 50 We have recently demonstrated that PKD2 is a critical regulator of tumour cell-EC communication by mediating hypoxia-induced VEGF production and secretion by the tumour cells and VEGF signalling in the ECs. 7 In this study, we aimed at further defining this signalling context of PKD2, the PKD isoform that is highly expressed in many tumours. We searched for novel PKD2 substrates that could have a role in angiogenesis using IVEC and identified a novel splice variant of human calcium and integrin-binding protein as a bona fide PKD2 substrate that we termed CIB1a. CIB1 regulates EC function in vitro, and contributes to angiogenesis in vivo. 30, 31, 43 In particular, it seems to be essential for proper EC signalling and functions such as migration, proliferation, nascent tubule formation and ischaemia-induced angiogenesis. 20 Moreover, CIB1 can regulate tumour growth and intratumoural microvessel density. 22 The protein binds to and regulates the activity of proteins including PAK1 28 and FAK 27 that are known to regulate EC function in vitro, and contribute to angiogenesis in vivo. 30, 31, 43 These data prompted us to further examine CIB1a as a potential substrate and downstream mediator of PKD2.
CIB1a was widely expressed, and its expression level in the tumour cell lines examined (AGS-gastric adenocarcinoma cells, Panc1 and MiaPaca2-pancreatic cancer cells and U87-glioblastoma cells) was even higher than that of CIB1. We identified Ser 118 as the PKD2 phosphorylation site in CIB1a. By generating a phospho-specific antibody against Ser 118 in CIB1a we show that CIB1a is phosphorylated by PKD2 in intact cells on stimulation with activators of PKDs such as PMA. CIB1a is not only a PKD2 substrate, but also physically interacts with the kinase, and we define the N-terminal AP-rich domain in PKD2 as the interaction site. This interaction is constitutive, but regulated by the phosphorylation status of CIB1a, with CIB1a being released from the interaction on phosphorylation by PKD2. As both PKD2 and CIB1 have been implicated in tumour growth and angiogenesis, we were interested whether phosphorylated CIB1a might mediate some of these functions downstream of PKD2. Tumour cells expressing nonphosphorylatable CIB1a gave rise to significantly smaller tumours on the CAM compared with tumour cells expressing CIB1a-WT. Conversely, tumours expressing the phosphomimetic CIB1a mutant were significantly larger than the tumours expressing the wild-type protein and exhibited a significantly higher proliferation index. Furthermore, phosphomimetic CIB1a partially restored tumour CIB1a mediates PKD2-induced tumour growth and angiogenesis M Armacki et al growth caused by depletion of PKD2. Thus, we provide evidence that CIB1a mediates in part the tumour growth-promoting properties of PKD2 that have been described previously. 39, 40 Our data also show that PKD2-phosphorylated CIB1a exerts its tumour-promoting effect not by direct stimulation of tumour cell proliferation, but indirectly via inducing tumour angiogenesis. Tumours expressing the phosphomimetic CIB1a mutant exhibit a significantly increased tumour angiogenesis as indicated by a higher desmin and von Willebrand factor immunoreactivity. PKD2 is activated by hypoxia and mediates both hypoxia-induced VEGF-A expression and VEGF-A secretion by the tumour cells. 7 Importantly, CIB1a phosphorylation at Ser 118 is also induced by hypoxia. VEGF-A expression in the tumour cells required CIB1a, but is independent of its phosphorylation status. However, the phosphomimetic CIB1a-S 118 E mutant significantly stimulated VEGF-A secretion by the tumour cells under hypoxic conditions. We could also identify the underlying mechanism. CIB1a phosphorylated at Ser 118 induces cargo transport from the TGN to the plasma membrane. Thus, CIB1a is a novel downstream effector of PKD2-mediating protein transport from the TGN to the plasma membrane. We also provide evidence that particularly phosphorylated CIB1a is localized at the TGN where it colocalizes with the TGN resident protein Golgin 97. The effect of CIB1a on the regulation of protein transport was specific. The phosphomimetic CIB1a mutant had no effect on secretion of FGF2 that is exported by an endoplasmic reticulum/Golgi-independent pathway, the so-called unconventional secretion. In line with our findings, VEGF secretion on expression of CIB1a-S 118 E was not only detectable in vitro, but also in the tumours growing on the CAM. Indeed, there was a marked increase in VEGF-A immunoreactivity particularly in the ECM of tumours expressing the phosphomimetic CIB1a mutant, indicative for increased VEGF secretion. There is increasing evidence that ECM binding regulates VEGF-dependent vascular patterning by controlling VEGF diffusion and gradients. 58 Proteolytic release of VEGF from the ECM can occur by cleavage of matrix-bound VEGF at its C-terminal domain or by cleavage of the ECM, and results in a diffusible VEGF that increases the soluble VEGF concentration, thereby potentiating the angiogenic switch and leading to neovascularization and tumour growth. 58 Thus, CIB1a mediates, at least in part, PKD2-induced VEGF-A secretion by the tumour cells in response to hypoxia and increases the VEGF-A content in the ECM, which is likely to contribute to its proangiogenic properties.
PKD2 and VEGF-A have been shown to promote tumour cell invasion [50] [51] [52] and CIB1 positively regulates cell migration and is necessary for the recruitment of FAK to the focal adhesions. 59 Our data show that in addition to increased angiogenesis, phosphorylation of CIB1a increases the invasiveness of the tumour cells both in vitro in matrigel and in vivo on the CAM. In contrast, cells expressing a non-phosphorylatable CIB1a mutant exhibit a markedly reduced invasive behaviour even compared with tumour cells expressing the wild-type protein. Thus, CIB1a is also a downstream mediator of PKD2-induced tumour cell invasion. The effect of phosphorylated CIB1a on tumour cell invasion on the CAM is at least in part caused by its proangiogenic effect. The precise molecular mechanisms underlying the effect of CIB1a on tumour cell invasion in vitro still remain to be elucidated in further studies. Taken together, we identify CIB1a as a novel PKD2 substrate and interactor. On phosphorylation by PKD2, CIB1a mediates tumour growth in vivo by promoting angiogenesis. At the molecular level, we show that PKDmediated phosphorylation of CIB1a mediates protein transport from the TGN to the plasma membrane thereby regulating VEGF-A secretion by the tumour cells. Thus, CIB1a is a novel downstream mediator of PKD2-induced protein transport and secretion and establish a new regulatory role for phosphorylated CIB1a in tumour growth, invasion and angiogenesis. Given the plethora of effects that are mediated by the PKD kinase family [60] [61] [62] targeting the substrates rather than the kinase itself might be a more specific therapeutic strategy. Our data suggest that CIB1a could be an interesting novel candidate for such a strategy.
MATERIALS AND METHODS
Cells and transfection
Cells were cultured in Dulbecco's modified Eagle's medium (Invitrogen, Karlsruhe, Germany) supplemented with 10% fetal calf serum (FCS; PAA, Coelbe, Germany) and 1% penicillin/streptomycin, as described previously. HeLa cells were transfected using TransIT HeLa Monster transfection kit according to manufacturer's instruction (Mirus Bio LLC, Madison, WI, USA). Transfection of HEK293-T was performed with polyethyleneimine (linear, MWB25000, Polysciences Inc., Warrington, PA, USA; stock concentration of 1 mg/ml) with a ratio of 1:7.5 (mg DNA: ml polyethyleneimine). 63 Virus supernatants were harvested after 48 h and used for transduction of Panc1 and HeLa cell lines. Cells were subsequently subjected to pyromycin selection to generate semi-stable cell lines used in assays. ShRNA Constructs: non-target shRNA control (scramble, shc002), and shRNA_PKD2 (Sigma-Aldrich, St Louis, MO, USA, NM_016457.x1720s1c1 (sh13D4); NM_016457.x-294s1c1 (sh13D5); NM_016457.x1767s1c1 (sh13D6); NM_016457.x-1335s1c1 (sh13D7)). E, DCRD, DC1a, DC1b, DPH and DKD have been described previously. 36 Deletion of amino acids 1-137 (PKD2-DAP) was performed in pcDNA3-PKD2-WT 36 with a 5 0 sense primer (5 0 -GCCACCTTCGAGGAATTCCAGAT-3 0 ) containing an EcoRI and a 3 0 antisense primer (5 0 -CATTGCTGGGATCCTGTGAAGAACC-3 0 ) containing a BamHI site. The fragment was cloned into an EcoRI-and BamHI-digested pEGFP-C2 vector (BD Biosciences Clontech, Erembodegem, Belgium). To clone the CIB1a, PCR on full-length CIB1a cDNA (cDNA library, Promega, Madison, WI, USA) was performed using the primers: 5 0 -GAGGCGAGTTG GCGGAG-3 0 and 5 0 -TGTGTCGACAGTGCGGGC-3 0 . PCR product was subcloned into pCR II-TOPO vector (Invitrogen), used as shuttle vector. CIB1a was then subcloned as an EcoRI/SalI fragment into pGEX-4T-1 (Amersham/GE Healthcare, Muenchen, Germany) or pCMV-Tag3B vector (Stratagene, La Jolla, CA, USA). To clone CIB1a into pIRES-AcEGFP (BD Biosciences Clontech), PCR of full-length CIB1a cDNA using pGEX4T-CIB1a as template was performed using the primers: 5'-TTGGTGGTGGC GACCATCC-3' and 5 0 -CTGGGGATCCTGTCACAGGACAA-3 0 . The resulting PCR product was digested with EcoRI and BamHI restriction enzymes, and subcloned into the pIRES-AcEGFP vector. Point mutations in the CIB1a sequence were generated using Quick-Change Site-Directed Mutagenesis Kit (Stratagene) according to the manufacturer's instruction using primers: 
The IVEC method
Plasmid-based human adult brain cDNA library is expressed using Promega's GoldTNT Express 96 Transcription/Translation System according to the manufactureŕs instructions. In all, 2.5 ml aliquots of the [ 35 S] methionine-labelled protein pools were mixed with phosphorylation buffer (20 mM Tris-HCl, pH7.5, 10% glycerol, 1.5 mM DTT, 150 nM microcystin-LR, 8 mM NaF, 0.15 mM Na 3 VO 4 , 10 mM MgOAc, 0.5 mM ATP), with or without 0.2 mM PKD2-2SE in a final volume of 15 ml. Samples were incubated at 30 1C for 50 min, and then the reactions were terminated by adding 3 Â SDS-PAGE sample buffer. The denatured samples were separated on a 10% SDS polyacrylamide gel (Bio-Rad Laboratories GmbH, Muenchen, Germany). After electrophoresis, the gels were fixed in a methanol/acetic acid/H 2 O solution (8/2/10, v/v/v) for 15 min, washed with distilled water for 10 min and vacuum dried. Labelled proteins were detected by 2-to 3-day exposure of Hyperfilm ECL film (Amersham/GE Healthcare). Films were examined for the presence of bands of altered mobility in the presence of added kinase. Once a pool possessing a candidate substrate was identified, the original cDNA pool was subdivided and retested until the single cDNA encoding the protein of interest was isolated.
